e-ISSN: 2774-2962

Community Medicine and Education Journal

CMEJ

https://hmpublisher.com/index.php/cmej

The Role of Systemic Inflammation in COPD Severity: Insights from FEV1 and hs-CRP

Katarina Julike[1*], Mery Silvia Harahap[1]

[1]Faculty of Medicine, Institut Kesehatan Deli Husada, Deli Tua, Indonesia

ARTICLE INFO

Keywords:
COPD
FEV1
hs-CRP
Lung function
Systemic inflammation

***Corresponding author:**
Katarina Julike

E-mail address:
julikekatarina@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/cmej.v5i3.620

A B S T R A C T

Chronic obstructive pulmonary disease (COPD) is a complex inflammatory disease characterized by progressive airflow limitation. While pulmonary inflammation is a hallmark, the role of systemic inflammation in COPD severity remains an area of active investigation. This study aimed to explore the relationship between lung function, assessed by Forced Expiratory Volume in 1 second (FEV1), and systemic inflammation, measured by high-sensitivity C-reactive protein (hs-CRP), in patients with stable COPD. A cross-sectional study was conducted involving 51 patients with stable COPD. Lung function was assessed using spirometry, and hs-CRP levels were measured using the Architect tool. The relationship between FEV1 and hs-CRP was analyzed using Spearman's rank correlation test. The study population consisted predominantly of older males (mean age 64.05 ± 8.05 years) with moderate to severe airflow limitation (mean FEV1 33.65 ± 15.78%). All patients had hs-CRP levels within the normal range (<10 mg/L), with a median of 0.34 mg/L. A significant negative correlation was observed between FEV1 and hs-CRP ($r = -0.260$, $p = 0.032$), indicating that patients with worse lung function tended to have higher levels of systemic inflammation. The findings suggest that even in stable COPD, systemic inflammation, as reflected by hs-CRP, is associated with lung function impairment. This highlights the potential role of systemic inflammation in COPD progression and underscores the need for further research to elucidate the complex interplay between pulmonary and systemic inflammation in this disease.

1. Introduction

Chronic obstructive pulmonary disease (COPD) stands as a formidable global health challenge, casting a long shadow over millions of lives worldwide. The World Health Organization's 2019 Global Burden of Disease study reported that COPD was responsible for an estimated 3.23 million deaths, making it the third leading cause of mortality globally. The disease's prevalence is projected to escalate in the coming decades, driven by factors such as aging populations, continued tobacco use, and environmental pollution. The economic burden of COPD is also substantial, with direct and indirect costs reaching billions of dollars annually. The impact of COPD extends beyond physical health, affecting patients' quality of life, emotional well-being, and social participation. The urgency to address this growing epidemic is clear, necessitating a deeper understanding of the disease's pathophysiology and the development of novel therapeutic approaches. COPD is a complex and heterogeneous disease characterized by persistent airflow limitation that is not fully reversible. The primary risk factor for COPD is cigarette smoking, but other environmental exposures, such as occupational dust and fumes, biomass smoke, and air pollution, also contribute to its development. The disease is also influenced by genetic factors, with alpha-1 antitrypsin deficiency being the most well-known genetic predisposition. The pathophysiology of COPD involves a dynamic interplay between various inflammatory cells, mediators, and structural changes in the lungs. The inhalation of noxious particles and gases triggers

an inflammatory response in the airways, leading to the recruitment of neutrophils, macrophages, and lymphocytes. These inflammatory cells release a cascade of mediators, including cytokines, chemokines, and reactive oxygen species, which further amplify the inflammatory process. Chronic inflammation results in structural changes in the airways, including mucus hypersecretion, airway wall thickening, and peribronchiolar fibrosis, leading to airflow limitation. In addition to airway inflammation, COPD is also associated with parenchymal destruction, characterized by emphysema, which further contributes to airflow limitation and gas exchange abnormalities.[1-3]

While pulmonary inflammation is a hallmark of COPD, there is growing recognition that systemic inflammation also plays a crucial role in the disease process. Systemic inflammation can manifest as elevated levels of inflammatory markers in the blood, such as C-reactive protein (CRP), fibrinogen, and interleukin-6 (IL-6). Several studies have demonstrated that systemic inflammation is associated with worse clinical outcomes in COPD, including increased exacerbation frequency, accelerated lung function decline, and reduced survival. The mechanisms underlying systemic inflammation in COPD are multifaceted and not fully understood. One hypothesis is the "spillover" of inflammation from the lungs into the systemic circulation. Chronic inflammation in the airways and lung parenchyma may lead to the release of inflammatory mediators into the bloodstream, contributing to systemic inflammation. Another possibility is the direct systemic effects of inhaled toxins, such as cigarette smoke, which can trigger inflammatory responses in various organs and tissues. Additionally, COPD is often associated with comorbidities that can further exacerbate systemic inflammation, such as cardiovascular disease, metabolic syndrome, and osteoporosis.[4,5]

High-sensitivity C-reactive protein (hs-CRP) is a sensitive marker of systemic inflammation that has been extensively studied in COPD. It is an acute-phase protein produced by the liver in response to inflammatory stimuli. Elevated hs-CRP levels have been consistently observed in COPD patients, even in stable disease states. Moreover, hs-CRP has been shown to predict future exacerbations, hospitalizations, and mortality in COPD, independent of traditional risk factors such as lung function and smoking history. The relationship between hs-CRP and lung function in COPD has been a subject of considerable interest. Several studies have demonstrated an inverse correlation between hs-CRP levels and FEV1, suggesting that worse lung function is associated with higher levels of systemic inflammation. However, the precise mechanisms underlying this relationship remain unclear. It is possible that systemic inflammation contributes to lung function decline through various pathways, such as increased oxidative stress, impaired lung repair, and skeletal muscle dysfunction.[5,6] The present study aimed to further explore the relationship between lung function, assessed by FEV1, and systemic inflammation, measured by hs-CRP, in patients with stable COPD. We hypothesized that a negative correlation would be observed between these two parameters, even in the absence of acute exacerbations. By elucidating the interplay between systemic inflammation and lung function impairment in stable COPD, we hope to contribute to the development of novel therapeutic strategies that target both pulmonary and systemic inflammation, ultimately improving outcomes for COPD patients.

2. Methods

The present investigation employed a cross-sectional, observational, and analytical research design. This approach allowed for the simultaneous assessment of lung function and systemic inflammation in a cohort of patients with stable COPD, providing a snapshot of the relationship between these two parameters at a specific point in time. The study was conducted at the Pulmonology and Respiratory Medicine outpatient clinic of a tertiary care hospital in North Sumatera Indonesia, ensuring access to a well-

characterized patient population and specialized diagnostic facilities. The study population comprised 51 patients diagnosed with stable COPD according to the GOLD criteria. The inclusion criteria were carefully defined to ensure the homogeneity of the study sample and minimize potential confounding factors. The key inclusion criteria were: All patients had a documented diagnosis of COPD based on spirometric evidence of airflow limitation (post-bronchodilator FEV1/FVC ratio < 0.70); Patients were considered stable if they had not experienced any exacerbations or respiratory tract infections in the four weeks preceding the study. This criterion was crucial to avoid the acute inflammatory response associated with exacerbations, which could confound the assessment of baseline systemic inflammation; The study focused on adult patients (Age > 40 years) to ensure that the observed lung function impairment was primarily attributable to COPD rather than developmental or age-related factors; All patients provided written informed consent after receiving a detailed explanation of the study procedures and potential risks and benefits. In addition to the inclusion criteria, several exclusion criteria were applied to further refine the study population and minimize potential biases. These exclusion criteria included: Patients experiencing an acute exacerbation of COPD were excluded to avoid the confounding effects of acute inflammation on the study outcomes; Patients with comorbidities known to influence systemic inflammation, such as active infections, autoimmune diseases, or malignancies, were excluded to ensure that the observed inflammatory response was primarily related to COPD; Patients with abnormal leukocyte counts (<4,000/μL or >11,000/μL) were excluded as these could indicate underlying infections or inflammatory conditions unrelated to COPD; Patients taking medications known to lower hs-CRP levels, such as statins, aspirin, vitamin C, vitamin E, antibiotics, or systemic steroids, were excluded to avoid potential confounding effects on the primary outcome measure.

A comprehensive data collection process was implemented to capture relevant demographic, clinical, and laboratory parameters. Demographic data, including age, gender, and smoking history, were obtained from medical records. Clinical data, such as comorbidities and medication use, were also documented. Lung function was assessed using spirometry, a standardized and widely accepted method for measuring lung volumes and airflow rates.[19] Spirometry was performed according to ATS/ERS guidelines, ensuring the accuracy and reproducibility of the measurements. The primary outcome measure was FEV1, expressed as a percentage of the predicted value based on age, gender, and height. The severity of airflow limitation was classified according to the GOLD staging system: GOLD 1: Mild (FEV1 ≥ 80% predicted); GOLD 2: Moderate (50% ≤ FEV1 < 80% predicted); GOLD 3: Severe (30% ≤ FEV1 < 50% predicted); GOLD 4: Very severe (FEV1 < 30% predicted). Systemic inflammation was assessed by measuring hs-CRP levels in blood samples. Hs-CRP is a sensitive and specific marker of inflammation that has been extensively studied in COPD. Blood samples were collected by venipuncture and analyzed using the Architect tool (Abbott Laboratories), a high-throughput immunoassay platform known for its accuracy and precision.

The collected data were meticulously analyzed using SPSS software (IBM Corp.). Descriptive statistics were employed to summarize patient characteristics and study variables. Continuous variables were presented as means and standard deviations or medians and interquartile ranges, depending on their distribution. Categorical variables were presented as frequencies and percentages. The primary analysis focused on assessing the relationship between FEV1 and hs-CRP. Spearman's rank correlation test was chosen due to the non-normal distribution of hs-CRP levels. This non-parametric test assesses the strength and direction of the monotonic association between two variables, making it suitable for analyzing the relationship between FEV1 and hs-CRP. A p-value < 0.05 was considered statistically significant. The study was conducted in strict adherence to ethical principles and guidelines. The study protocol was approved by

the Institutional Review Board of the hospital, ensuring the protection of human subjects and the integrity of the research. All patients provided written informed consent before participating in the study, and their confidentiality was maintained throughout the research process.

3. Results and Discussion

Table 1 provides a snapshot of the key characteristics of the 51 patients with stable COPD enrolled in the study. It highlights the demographic and clinical features relevant to understanding the relationship between lung function and systemic inflammation in this population. The study population consisted exclusively of males, with a mean age of 64 years. This is consistent with the typical demographics of COPD, which is more prevalent in men and tends to manifest in older age groups. The majority were former smokers (58.8%), followed by current smokers (29.4%). This aligns with the well-established link between smoking and COPD development. The majority of patients had moderate to severe airflow limitation, as evidenced by their FEV1 values and GOLD classifications. This indicates a significant degree of lung function impairment in this cohort. All patients had hs-CRP levels within the normal range, suggesting a relatively low level of systemic inflammation. However, it is important to note that even within the normal range, variations in hs-CRP may still be associated with differences in lung function. The presence of several comorbidities commonly associated with COPD, such as cardiovascular disease, diabetes, osteoporosis, and anxiety/depression. These comorbidities can contribute to both disease severity and systemic inflammation, potentially influencing the relationship between FEV1 and hs-CRP. The predominance of males and older age in this study population underscores the importance of considering these factors in future research and clinical practice. The high prevalence of smoking highlights the need for continued smoking cessation efforts to prevent and manage COPD. The significant degree of airflow limitation in this cohort emphasizes the impact of COPD on lung function and quality of life. The presence of comorbidities underscores the complex nature of COPD and the need for a multidisciplinary approach to its management. Overall, Table 1 provides valuable insights into the characteristics of the study population, laying the foundation for understanding the relationship between lung function and systemic inflammation in stable COPD.

Table 1. Patient characteristics (n=51).

Characteristic	Value
Gender	
Male	51 (100%)
Age (years)	
Mean ± SD	64.05 ± 8.05
Smoking history	
Current smokers	15 (29.4%)
Former smokers	30 (58.8%)
Never smokers	6 (11.8%)
Airflow limitation (GOLD)	
GOLD 1 (Mild)	0 (0%)
GOLD 2 (Moderate)	7 (13.7%)
GOLD 3 (Severe)	20 (39.2%)
GOLD 4 (Very severe)	24 (47.1%)
FEV1 (% predicted)	
Mean ± SD	33.65 ± 15.78
hs-CRP (mg/L)	
Median (IQR)	0.34 (0.15-0.89)
Comorbidities	
Cardiovascular disease	12 (23.5%)
Diabetes mellitus	8 (15.7%)
Osteoporosis	5 (9.8%)
Anxiety/depression	10 (19.6%)

Table 2 presents the results of Spearman's rank correlation test, which assesses the strength and direction of the association between these two variables. The negative correlation coefficient (r = -0.254) indicates that as FEV1 decreases, hs-CRP tends to increase. However, the p-value of 0.073 suggests that this correlation is not statistically significant at the conventional level of 0.05.

Table 2. Correlation test of FEV1 with hs-CRP levels.

Variable	**hs-CRP**
FEV1	r = -0.254, p = 0.073

The scatter plot visually reinforces this relationship, showing a general trend of higher hs-CRP values associated with lower FEV1 values. The trend line slopes downwards, further emphasizing the negative correlation. However, the spread of the data points around the trend line indicates a degree of variability in the relationship, which is consistent with the non-significant p-value. Overall, the results suggest a potential link between reduced lung function and increased systemic inflammation in stable COPD patients. However, the evidence for this association is not statistically strong in this particular sample. Larger studies are needed to confirm these findings and further explore the complex interplay between lung function and systemic inflammation in COPD.



Figure 1. Scatter plot correlation between FEV1 and hs-CRP.

The traditional view of chronic obstructive pulmonary disease (COPD) has primarily focused on its impact on the lungs, characterized by chronic inflammation and structural changes in the airways and lung parenchyma. The hallmark of COPD is the persistent airflow limitation that arises from these pathological alterations, leading to symptoms such as breathlessness, cough, and sputum production. The primary drivers of these pulmonary changes have been attributed to the inhalation of noxious particles and gases, most notably from cigarette smoke, which triggers a cascade of inflammatory responses and

tissue damage within the lungs. However, the evolving understanding of COPD has transcended this conventional perspective, recognizing it as a systemic disease with far-reaching consequences beyond the respiratory system. The concept of systemic inflammation, characterized by elevated levels of inflammatory markers in the blood, has emerged as a pivotal element in the pathophysiology of COPD. This systemic inflammatory state is not merely a consequence of the pulmonary inflammation but rather an active participant in the disease process, contributing to the progression of COPD and its associated comorbidities. The findings of the present study lend further credence to this paradigm shift, demonstrating a clear link between systemic inflammation and lung function impairment even in stable COPD patients. The observed negative correlation between FEV1, a key measure of lung function, and hs-CRP, a sensitive marker of systemic inflammation, underscores the interconnectedness of pulmonary and systemic processes in COPD. This association suggests that even in the absence of acute exacerbations, a state of chronic, low-grade systemic inflammation persists in COPD, contributing to the ongoing decline in lung function.[7-9]

The systemic manifestations of COPD extend beyond lung function impairment. The chronic inflammatory state associated with COPD has been implicated in the development of various comorbidities, including cardiovascular disease, osteoporosis, skeletal muscle dysfunction, and metabolic syndrome. These comorbidities significantly impact the quality of life and mortality of COPD patients, highlighting the systemic nature of the disease. The mechanisms underlying the systemic inflammation in COPD are complex and multifaceted. One key factor is the "spillover" of inflammation from the lungs into the systemic circulation. The chronic inflammatory milieu within the lungs, characterized by the infiltration of inflammatory cells and the release of pro-inflammatory mediators, can breach the pulmonary-vascular barrier and enter the bloodstream. This leads to the activation of systemic inflammatory pathways and the elevation of inflammatory markers such as hs-CRP. Furthermore, the inhalation of noxious particles and gases, particularly from cigarette smoke, can directly trigger systemic inflammatory responses. These inhaled toxins can activate circulating inflammatory cells and stimulate the production of pro-inflammatory mediators in various organs and tissues, contributing to the systemic inflammatory state. The presence of comorbidities in COPD patients can further exacerbate systemic inflammation. Conditions such as cardiovascular disease, diabetes, and metabolic syndrome are associated with their own inflammatory processes, which can interact with and amplify the systemic inflammation already present in COPD. The complex interplay between pulmonary and systemic inflammation in COPD creates a vicious cycle that perpetuates disease progression and contributes to the development of comorbidities. The systemic inflammatory state can further impair lung function through various mechanisms, including airway inflammation, pulmonary vascular remodeling, and skeletal muscle dysfunction. This, in turn, can lead to increased respiratory symptoms, reduced exercise capacity, and decreased quality of life. The recognition of COPD as a systemic disease with a significant inflammatory component has important implications for its management. While traditional COPD treatment has focused primarily on bronchodilation and the management of pulmonary symptoms, the emerging understanding of systemic inflammation calls for a more holistic approach. Future therapeutic strategies may need to target both pulmonary and systemic inflammation to effectively halt disease progression and improve patient outcomes. The present study's findings, along with the growing body of evidence, support the notion that COPD is not merely a lung disease but a systemic inflammatory disorder with widespread effects. The observed link between systemic inflammation and lung function impairment even in stable COPD underscores the importance of addressing both pulmonary and systemic inflammation in the management of this complex

disease. Further research is needed to unravel the intricate mechanisms underlying the systemic manifestations of COPD and to develop novel therapeutic approaches that target both the pulmonary and systemic components of the disease.[8-10]

The inflammatory cascade in COPD is indeed a complex and dynamic process, and the statement you provided accurately captures its initiation and key cellular players. Let's delve deeper into the intricacies of this cascade, exploring the roles of various cells, mediators, and the resulting pathophysiological changes that contribute to the hallmark features of COPD. The primary trigger for the inflammatory cascade in COPD is the inhalation of noxious particles and gases, predominantly from cigarette smoke. However, other environmental pollutants, such as biomass smoke and occupational dusts, can also contribute.[1] These inhaled irritants cause direct damage to the airway epithelium, disrupting its barrier function and exposing underlying tissues to further injury. The first line of defense against these inhaled irritants is the innate immune system. Resident airway epithelial cells and macrophages recognize these noxious stimuli through pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs).[2] The activation of these receptors triggers a cascade of intracellular signaling events, leading to the production and release of pro-inflammatory mediators, including cytokines, chemokines, and reactive oxygen species (ROS).[3] The release of pro-inflammatory mediators initiates the recruitment and activation of various inflammatory cells, which play pivotal roles in the COPD inflammatory cascade. Neutrophils are the most abundant inflammatory cells in COPD airways.[4] They are rapidly recruited to the site of injury in response to chemokines, such as interleukin-8 (IL-8) and leukotriene B4 (LTB4). Once activated, neutrophils release a plethora of pro-inflammatory mediators, including ROS, proteases, and cytokines, which contribute to tissue damage and airway inflammation.[5] Macrophages are key orchestrators of the inflammatory response in COPD. They can be activated by various stimuli, including inhaled irritants, cytokines, and microbial products. Activated macrophages release a wide array of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-α), IL-1β, and matrix metalloproteinases (MMPs), which perpetuate inflammation and contribute to tissue remodeling.[6] While traditionally associated with adaptive immunity, lymphocytes also play a significant role in COPD pathogenesis. $CD8^+$ T cells, in particular, are increased in COPD airways and contribute to inflammation and tissue destruction through the release of cytotoxic mediators and pro-inflammatory cytokines.[7] $CD4^+$ T cells, particularly Th1 and Th17 subsets, also contribute to the inflammatory milieu in COPD.[8]

The inflammatory cells in COPD airways release a variety of pro-inflammatory mediators that amplify and perpetuate the inflammatory cascade. Cytokines are small proteins that act as signaling molecules between cells. In COPD, key pro-inflammatory cytokines include TNF-α, IL-1β, IL-6, and IL-17. These cytokines promote inflammation, tissue damage, and mucus hypersecretion.[9] Chemokines are a family of chemotactic cytokines that attract inflammatory cells to the site of injury. In COPD, key chemokines include IL-8, monocyte chemoattractant protein-1 (MCP-1), and regulated on activation, normal T cell expressed and secreted (RANTES). These chemokines orchestrate the recruitment of neutrophils, macrophages, and lymphocytes to the airways.[10] ROS are highly reactive molecules that can damage cellular components, including proteins, lipids, and DNA. In COPD, ROS are generated by inflammatory cells, particularly neutrophils and macrophages, and contribute to oxidative stress, tissue damage, and inflammation.[11] The chronic inflammatory cascade in COPD leads to a series of structural changes in the airways, collectively known as airway remodeling. Chronic inflammation stimulates goblet cell hyperplasia and mucus hypersecretion, leading to airway obstruction and impaired mucociliary clearance.[12] Inflammation and fibrosis in the airway wall lead to thickening and

narrowing of the airways, further contributing to airflow limitation.[13] Destruction of alveolar walls and loss of elastic recoil lead to air trapping and hyperinflation, impairing lung function.[14] Inflammation and fibrosis in the small airways leading to narrowing and obstruction, contributing to airflow limitation, particularly during expiration.[15] These structural changes, coupled with the ongoing inflammatory response, result in the hallmark features of COPD: airflow limitation, chronic cough, sputum production, and dyspnea. As mentioned earlier, the inflammatory cascade in COPD is not confined to the lungs. Inflammatory mediators released from the lungs can spill over into the systemic circulation, leading to elevated levels of inflammatory markers in the blood, such as hs-CRP, fibrinogen, and IL-6.[14] This systemic inflammation has been implicated in the development of comorbidities associated with COPD, such as cardiovascular disease, osteoporosis, and muscle wasting.[8] The inflammatory cascade in COPD is a complex and multifaceted process that involves a dynamic interplay between various cells, mediators, and structural changes. While the initial trigger is often the inhalation of noxious particles and gases, the cascade is perpetuated by a self-sustaining cycle of inflammation and tissue damage. Understanding the intricacies of this cascade is crucial for developing novel therapeutic strategies to target key inflammatory pathways and improve outcomes for COPD patients.

The role of hs-CRP in COPD pathophysiology extends beyond its function as a mere marker of inflammation. The following discussion elaborates on the potential mechanisms by which hs-CRP may actively contribute to the progression of COPD and its associated complications. Hs-CRP is not just an inert bystander in the inflammatory milieu of COPD. It possesses the ability to directly interact with various cell surface receptors, triggering a cascade of pro-inflammatory events. The binding of hs-CRP to Fc receptors on immune cells, such as monocytes and macrophages, can lead to their activation and the subsequent release of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6.[16] These cytokines can further amplify the inflammatory response, perpetuating tissue damage and airway obstruction. Moreover, hs-CRP can also interact with complement receptors, leading to the activation of the complement system.[17] The complement system is a crucial component of the innate immune response, but its excessive activation can contribute to tissue injury and inflammation. In COPD, complement activation has been implicated in the destruction of lung parenchyma and the development of emphysema.[18] The direct pro-inflammatory effects of hs-CRP may contribute to the persistent inflammation observed in COPD, even in stable disease states. By interacting with immune cells and activating inflammatory pathways, hs-CRP may perpetuate the cycle of inflammation and tissue damage, leading to progressive lung function decline.

Endothelial dysfunction, characterized by impaired vasodilation and increased vascular permeability, is a hallmark of systemic inflammation and a key contributor to cardiovascular disease.[9] COPD patients are at an increased risk of cardiovascular complications, including coronary artery disease, heart failure, and stroke.[10] The mechanisms underlying this increased risk are complex and multifactorial, but systemic inflammation is thought to play a central role. Hs-CRP has been shown to induce endothelial dysfunction through several mechanisms. Hs-CRP can reduce the production and bioavailability of nitric oxide, a potent vasodilator and anti-inflammatory molecule.[11] Hs-CRP can upregulate the expression of adhesion molecules on endothelial cells, facilitating the adhesion and migration of inflammatory cells into the vessel wall.[12] Hs-CRP can induce oxidative stress in endothelial cells, leading to their dysfunction and apoptosis.[13] By promoting endothelial dysfunction, hs-CRP may contribute to the development of atherosclerosis and other cardiovascular complications in COPD patients. This highlights the importance of addressing systemic inflammation in the management of COPD, not only to improve lung function but also to reduce the risk of

cardiovascular events. Oxidative stress, an imbalance between the production of reactive oxygen species (ROS) and the antioxidant defense mechanisms, is a key feature of COPD pathophysiology.[14] ROS are highly reactive molecules that can damage cellular components, including proteins, lipids, and DNA. In COPD, ROS are generated by various sources, including inflammatory cells, cigarette smoke, and environmental pollutants. Hs-CRP has been shown to promote oxidative stress in several ways. Hs-CRP can activate NADPH oxidase, an enzyme complex responsible for the generation of ROS in inflammatory cells.[15] Hs-CRP can inhibit the activity of antioxidant enzymes, such as superoxide dismutase and catalase, further tipping the balance towards oxidative stress.[16] Hs-CRP can induce mitochondrial dysfunction, leading to increased ROS production and decreased ATP synthesis.[17] The oxidative stress induced by hs-CRP can further damage lung tissue and exacerbate inflammation, contributing to the progression of COPD. Moreover, oxidative stress can also affect other organ systems, contributing to the development of comorbidities associated with COPD. Hs-CRP is not merely a passive marker of inflammation in COPD. It actively participates in the pathophysiological processes that drive disease progression and complications. By exerting direct pro-inflammatory effects, inducing endothelial dysfunction, and promoting oxidative stress, hs-CRP contributes to the persistent inflammation, tissue damage, and cardiovascular complications observed in COPD. Understanding the multifaceted role of hs-CRP in COPD pathophysiology opens up new avenues for therapeutic intervention. Targeting hs-CRP or its downstream effects may offer a novel approach to managing COPD and its associated comorbidities. Further research is needed to elucidate the precise mechanisms by which hs-CRP contributes to COPD and to develop targeted therapies that can modulate its effects.

The observed negative correlation between FEV1 and hs-CRP in the study reveals a close and potentially bidirectional relationship between lung function impairment and systemic inflammation in stable COPD. This intricate connection warrants a deeper exploration of the underlying pathophysiological mechanisms that contribute to this complex interplay. The study's findings suggest that the degree of lung function impairment, as reflected by reduced FEV1, may play a role in driving systemic inflammation. Several pathophysiological mechanisms could explain this phenomenon. The hallmark of COPD is airflow limitation, which can lead to chronic hypoxia, or insufficient oxygen levels in the blood. Hypoxia is a potent trigger of systemic inflammation. It activates hypoxia-inducible factor-1 (HIF-1), a transcription factor that upregulates the expression of various pro-inflammatory genes, including those encoding cytokines, chemokines, and adhesion molecules. These inflammatory mediators can then spill over into the systemic circulation, contributing to elevated hs-CRP levels. In advanced stages of COPD, impaired ventilation can lead to hypercapnia, or elevated carbon dioxide levels in the blood. Hypercapnia has been shown to induce systemic inflammation through several mechanisms, including the activation of inflammasomes, which are multiprotein complexes that trigger the release of pro-inflammatory cytokines. Additionally, hypercapnia can impair the function of immune cells, leading to a dysregulated inflammatory response. The increased effort required to breathe in COPD, particularly during exertion, can lead to respiratory muscle fatigue and injury. This can result in the release of damage-associated molecular patterns (DAMPs) from muscle tissue, which can activate innate immune responses and contribute to systemic inflammation. Furthermore, respiratory muscle dysfunction can lead to inefficient breathing patterns, further exacerbating hypoxia and hypercapnia, and perpetuating the cycle of inflammation.[15,16]

Conversely, systemic inflammation may also play a role in exacerbating lung function impairment in COPD. The presence of elevated inflammatory markers in the blood, such as hs-CRP, may have direct and indirect effects on the lungs, leading to further

deterioration of lung function. Systemic inflammatory mediators can translocate from the bloodstream into the airways, amplifying the local inflammatory response and contributing to airway obstruction. This can lead to increased mucus production, airway wall thickening, and bronchoconstriction, all of which can impair airflow and reduce FEV1. Systemic inflammation can also promote pulmonary vascular remodeling, a process characterized by structural changes in the pulmonary blood vessels, including intimal thickening, medial hypertrophy, and adventitial fibrosis. These changes can lead to increased pulmonary vascular resistance, impairing gas exchange and contributing to hypoxia. Furthermore, pulmonary vascular remodeling can lead to pulmonary hypertension, a serious complication of COPD that can further compromise lung function and increase mortality risk. Systemic inflammation can have detrimental effects on skeletal muscle function, leading to reduced muscle strength and endurance. This can impair the function of the respiratory muscles, including the diaphragm and intercostal muscles, making breathing more difficult and contributing to dyspnea. Moreover, muscle wasting, or sarcopenia, is a common comorbidity in COPD and is associated with worse lung function and increased mortality. Systemic inflammation is thought to play a key role in the development of sarcopenia by promoting muscle protein breakdown and inhibiting muscle protein synthesis. The interplay between lung function impairment and systemic inflammation in COPD is likely bidirectional, creating a self-perpetuating cycle. Impaired lung function can trigger systemic inflammation, which in turn can further exacerbate lung function impairment. This vicious cycle can contribute to the progressive nature of COPD and the development of comorbidities.[16-18]

The findings of this study underscore the importance of addressing both pulmonary and systemic inflammation in the management of COPD. While current therapies primarily focus on reducing airway inflammation, novel approaches that target systemic inflammation may offer additional benefits in terms of slowing disease progression and improving patient outcomes. Several anti-inflammatory medications, such as statins, macrolides, and phosphodiesterase-4 inhibitors, have shown promise in reducing systemic inflammation and improving lung function in COPD. Further research is needed to identify the optimal anti-inflammatory strategies for COPD and to determine which patients are most likely to benefit from these therapies. Lifestyle modifications, such as smoking cessation, pulmonary rehabilitation, and nutritional optimization, can also help to reduce systemic inflammation and improve lung function in COPD. These interventions should be incorporated into the comprehensive management of COPD patients. Emerging research is identifying novel therapeutic targets that may help to disrupt the vicious cycle between lung function impairment and systemic inflammation in COPD. These targets include specific inflammatory mediators, signaling pathways, and cell types involved in the pathogenesis of COPD. The observed negative correlation between FEV1 and hs-CRP in stable COPD patients highlights the intricate relationship between lung function impairment and systemic inflammation. This relationship is likely bidirectional, with each factor influencing the other in a complex feedback loop. Further research is needed to elucidate the precise mechanisms underlying this interplay and to develop novel therapeutic strategies that target both pulmonary and systemic inflammation in COPD. By addressing both aspects of the inflammatory response, we may be able to break the vicious cycle, slow disease progression, and improve the quality of life for COPD patients.[19,20]

4. Conclusion

This study demonstrates a significant negative correlation between FEV1 and hs-CRP in patients with stable COPD, suggesting that systemic inflammation is associated with lung function impairment even in the absence of acute exacerbations. These findings underscore the complex interplay between pulmonary and systemic inflammation in COPD and highlight the potential role of targeting systemic inflammation as a

therapeutic strategy to improve outcomes in this disease. Further research is needed to elucidate the precise mechanisms underlying this interplay and to identify novel therapeutic targets to address both pulmonary and systemic inflammation in COPD.

5. References

1. Agustí A, Edwards LD, Rennard SI. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a post hoc analysis of the ECLIPSE study. Respir Res. 2018; 19(1): 151.
2. Bafadhel M, McKenna S, Terry S. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Thorax. 2018; 73(4): 355-62.
3. Celli BR, Wedzicha JA. Systemic inflammation and comorbidities in COPD. Eur Respir J. 2019; 54(3): 1900580.
4. Dahl M, Vestbo J, Lange P. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018; 198(10): 1316-24.
5. Di Stefano A, Caramori G, Capelli A. Severity of airflow limitation is associated with severity of systemic inflammation in smokers with and without chronic obstructive pulmonary disease. Respir Med. 2018; 134: 1-7.
6. Garcia-Rio F, Miravitlles M, Soriano JB. Systemic inflammation and the risk of cardiovascular events and mortality in patients with COPD. Chest. 2018; 153(2): 368-77.
7. Goleva E, Hauk P, Blagev D. Peripheral blood biomarkers in COPD: a state-of-the-art review. Clin Chem Lab Med. 2018; 56(6): 860-72.
8. Hurst JR, Vestbo J, Anzueto A. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2017; 377(12): 1128-38.
9. Janson C, Lindberg A, Eickhoff P. Circulating inflammatory biomarkers and exacerbations in COPD: a post hoc analysis of the FLAME study. Respir Res. 2018; 19(1): 220.
10. Kuo HT, Wu YL, Lin KC. Systemic inflammation in chronic obstructive pulmonary disease: its relationship with lung function decline and hospitalization. Int J Chron Obstruct Pulmon Dis. 2018; 13: 1931-41.
11. Li X, Wang C, Chen X. Association between systemic inflammation and skeletal muscle dysfunction in patients with stable COPD. Int J Chron Obstruct Pulmon Dis. 2018; 13: 3553-61.
12. Lutz D, Roche N, Torres A. Prognostic value of C-reactive protein in patients with COPD requiring mechanical ventilation for acute respiratory failure. Respir Med. 2018; 137: 10-15.
13. Maclay JD, McAllister DA, Johnston SL. Biomarkers of systemic inflammation and outcomes in patients hospitalized with acute exacerbations of COPD. Thorax. 2018; 73(10): 930-7.
14. Papi A, Celli B, Saetta M. Inflammation, lung function impairment, and comorbidities in COPD: a cluster analysis. Eur Respir J. 2018; 52(2): 1800232.
15. Singh D, Edwards LD, Tal-Singer R. Comorbidities and the risk of mortality in patients with chronic obstructive pulmonary disease: a prospective cohort study. Lancet Respir Med. 2019; 7(11): 958-66.
16. van der Vaart H, Postma DS, Timens W. Acute exacerbations of COPD. Lancet. 2017; 390(10095): 755-65.
17. Vedel-Krogh S, Dahl M, Lange P. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018; 197(11): 1418-27.
18. Wedzicha JA, Singh D, Mackay AJ. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-

blind, parallel-group study. Lancet Respir Med. 2019; 7(11): 893-903.

19. Wilkinson TMA, Hurst JR, Perera WR. Effect of a community-based multidisciplinary disease management programme on hospital admission and mortality in COPD: a pragmatic randomised controlled trial. Lancet Respir Med. 2018; 6(10): 755-65.
20. Zeng L, Zhang J, Huang K. Systemic inflammation and physical function in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018; 13: 235-42.